Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

Liselore Loverix,Ignace Vergote,Pieter Busschaert,Adriaan Vanderstichele,Tom Venken,Bram Boeckx,Philipp Harter,Hilde Brems,Els Van Nieuwenhuysen,Sandro Pignata,Thaïs Baert,Antonio Gonzalez-Martin,Sileny Han,Christian Marth,Patrick Neven,Nicoletta Colombo,Patrick Berteloot,Johanna Mäenpää,Siel Olbrecht,Tina Laga

European Journal of Cancer（2023）

Cited 3|Views27
No score
Abstract
•Results of ENGOT HRD initiative on 468 shared FFPE samples of the PAOLA-1 trial.•Academic Leuven HRD test shows comparable results with Myriad MyChoice HRD test.•Leuven HRD test confirms the impact of olaparib on PFS and OS in the HRD+ patients.
More
Translated text
Key words
ovarian cancer patients,leuven hrd test,inhibitor
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined